Biotech Unusual Volume: Repligen Corporation (NASDAQ:RGEN), Zalicus (NASDAQ:ZLCS), Evogene (NYSE:EVGN), Keryx Biopharmaceuticals (NASDAQ:KERX)

On March 6, 2014, Repligen Corporation (NASDAQ:RGEN) announced its financial results and corporate update for the fourth quarter and year ended December 31, 2013. Repligen Corporation (NASDAQ:RGEN) shares after opening at $15.30 moved to $16.22 on last trade day and at the end of the day closed at $15.84. Company price to sales ratio in past twelve months was calculated as 7.44 and price to cash ratio as 8.24. Repligen Corporation (NASDAQ:RGEN) showed a positive weekly performance of 15.79%.

Yesterday, Zalicus Inc. (NASDAQ:ZLCS) revealed it had confirmed a deal with Epirus Biopharmaceuticals for a merger of the latter with a Zalicus subsidiary in an all-stock transaction.
Zalicus Inc. (NASDAQ:ZLCS) shares fell -10.37% in last trading session and ended the day on $1.21. ZLCS return on equity ratio is recorded as -172.70% and its return on assets is -80.20%. Zalicus Inc. (NASDAQ:ZLCS) yearly performance is -63.33%.

Evogene Ltd. (NYSE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced that it will release its financial results for the first quarter of 2014 on Wednesday, May 7, 2014. Evogene Ltd (NYSE:EVGN) shares moved down -4.72% in last trading session and was closed at $16.77, while trading in range of $16.40 – $17.00. Evogene Ltd (NYSE:EVGN) year to date (YTD) performance is -14.66%.

Equities researchers at Ladenburg Thalmann increased their price objective on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from $24.00 to $30.00 in a research report issued on Friday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s price target points to a potential upside of 89.87% from the company’s current price. Keryx Biopharmaceuticals (NASDAQ:KERX) weekly performance is -8.50%. On last trading day company shares ended up $13.46. Keryx Biopharmaceuticals (NASDAQ:KERX) distance from 50-day simple moving average (SMA50) is -13.41%. Analysts mean target price for the company is $25.64.